Therefore, the pan-Trk inhibitor, CEP-701 entered with great promises the phase-I clinical trial in PC patients [81], and phase-II clinical trials are still in progress in asymptomatic hormone-refractory PC patients. Here, NTRK1 is linked to pachyonychia congenita.